LL-37

LL-37 is the sole human member of the cathelicidin family of host-defense (antimicrobial) peptides, derived from proteolytic cleavage of the precursor protein hCAP18. As a 37-residue cationic, amphipathic peptide, it is a long-standing subject of academic and preclinical investigation in immunology, microbiology, and tissue-repair biology. In a wholesale catalog context within the Healing and Recovery category, this presentation is supplied strictly as a research compound for laboratory and professional reference use. LL-37 is not approved by the FDA for therapeutic use, and the material described here is intended for research and professional-use applications rather than patient care. The summary below reflects general areas of scientific interest reported in the published literature and should not be read as a representation of clinical performance; individual results vary.

• Investigated in preclinical and in vitro literature for its reported role in innate-immune host defense and modulation of microbial activity; individual results vary.
• Studied in research models for its reported involvement in wound-healing and tissue-repair signaling pathways; individual results vary.
• Examined in the scientific literature for reported interactions with biofilms and microbial membranes under laboratory conditions; individual results vary.
• Explored in research settings for its proposed influence on angiogenesis and cell-migration processes relevant to recovery biology; individual results vary.
• Reported in immunology research as a proposed modulator of inflammatory and cell-signaling responses in experimental systems; individual results vary.

Reference handling information only. This compound is commonly supplied as a lyophilized powder for reconstitution with bacteriostatic or sterile water. As a general storage reference, reconstituted material is typically kept refrigerated (approximately 2-8 C), protected from light, and not subjected to repeated freeze-thaw cycles, while lyophilized material is commonly stored frozen and protected from light and moisture until reconstitution, with handling under aseptic conditions. This is general storage and handling reference information and does not constitute a usage or dosing protocol. All clinical and research protocols, including any decision regarding preparation, dosing, and administration, are determined solely by the licensed ordering provider, and this material is provided for reference and professional use only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published preclinical literature, LL-37 is described as a cationic, amphipathic peptide that associates with negatively charged microbial membranes, where it is proposed to disrupt membrane integrity and contribute to host-defense activity. Beyond this direct membrane interaction, research models suggest LL-37 may engage host cell-surface receptors and intracellular signaling pathways implicated in chemotaxis, cell migration, angiogenesis, and the regulation of inflammatory mediators. These mechanisms are characterized as studied or proposed based on experimental systems rather than established clinical effects, and observed outcomes are reported to vary across models and conditions; individual results vary.